摘要
目的探讨血栓通粉针联合尼莫地平治疗早期脑梗死的临床疗效并探讨其对血清超敏C-反应蛋白(high sensitivity C-Reactive Protein,hs-CRP)的影响。方法将符合入选标准的102例早期脑梗死患者随机分为联合治疗组和对照组,均为51例。在一般治疗基础上,治疗组应用血栓通粉针联合尼莫地平治疗,对照组患者应用尼莫地平治疗,疗程均为14d。两组治疗前后均进行神经功能缺损评分及血清hs-CRP水平测定。结果联合治疗组总有效率(92.2%)明显高于对照组(76.5%)(P<0.05)。14d时,治疗组血清hs-CRP水平较对照组明显降低(P<0.05)。结论血栓通粉针联合尼莫地平治疗早期脑梗死的临床疗效确切,并可降低脑梗死患者血清hs-CRP水平,减轻血管炎性反应,值得临床推广。
Objective To investigate the combination of Xueshuangtong and nimodipine in the treat- ment of early cerebral infarction and explore its clinical impact on serum hlgh-sensitivity C-reactive protein （ hs- CRP）. Methods Selected cases of early cerebral infarction （ n = 102 ）were randomly divided into combined treatment group and control group（51 cases each）. Based on the general therapy, treatment group received combination of Xueshuangtong and nimodipine and the control group patients only nimodipine, total treatment regimen were 14 d. The neurological deficit scores and serum levels of hs-CRP were recorded in the two groups before and after treatment. Results The total effective rate in treatment group （92. 2% ） was significantly higher than that of the control group（76. 5% ） （P 〈0. 05）. At 14 d, the hs-CRP levels in the treatment group was significantly lower than that in the control group（P 〈0. 05）. Conclusions Combination of Xueshuangtong and nimodipine in the treatment of early cerebral infarction has actual clinical efficacy, and can reduce serum hs- CRP levels in patients with cerebral infarction, suppress acute cerebrovascular inflammatory response, which is well worth popularizing.
出处
《中国实用医药》
2009年第35期8-9,共2页
China Practical Medicine
关键词
脑梗死
血栓通粉针
尼莫地平
超敏C-反应蛋白
治疗
Cerebral infarction
Xueshuangtong
Nimodipine
High-sensitivity C-reactive protein
Treatment
